Evaluation of the analytical performances of the Cobas c513 analyser for HbA(1c) assay

INTRODUCTION: Haemoglobin A(1c) (HbA(1c)) is considered to be the gold standard for the follow-up of glycaemic control in patients with diabetes mellitus and is also a diagnostic tool. Accordingly, reliable and efficient methods must be used for its quantification. Roche Diagnostics have recently adapted the Tina-quant® HbA(1c) Third Generation immunoassay on a fully dedicated analyser, the Cobas c513, which allows a high throughput of up to 400 samples per hour. The present article deals with the evaluation of the analytical performances of this system which has been recently introduced to the market. MATERIALS AND METHODS: Precision, comparison with two ion-exchange high-performance liquid chromatography (HPLC) methods (Variant II and D-100 systems, BioRad Laboratories) using Passing Bablok and Bland-Altman analyses, accuracy and interference of the most frequent haemoglobin (Hb) variants on HbA(1c) measurement were evaluated. RESULTS: Precision was high, with coefficients of variation lower than 1.1% (HbA(1c) values expressed in National Glycohemoglobin Standardization Program units, 1.7% for values expressed in International Federation of Clinical Chemistry and Laboratory Medicine [IFCC] units). The comparison study showed similar results with the two HPLC systems. The analysis of samples with IFCC-assigned values showed high methodological accuracy. Finally, no interference of bilirubin, triglycerides and common Hb variants (Hb AC, AD, AE, AS) was observed. CONCLUSIONS: This evaluation showed that the analytical performance of the Cobas c513 analyser for HbA(1c) assay makes it suitable for a routine use in clinical chemistry laboratories.